ライフサイエンスコーパス: reduction in risk

1 at comprehensive UM can produce a significant and sustained reduction in risk-adjusted per-patient year outpatient high-c

2 For equal time since quitting, the reduction in risk among women seemed less marked than among m

3 ectively, (P = 0.048)].There are greater body weight and WC reductions in risk carriers than in nonrisk carriers of the F

4 There were net reductions in risk factor values up to six years after the ch

5 physical activity is associated with better outcomes and a reduction in risk factors for cardiovascular disease are inco

6 steryl ester transfer protein) have failed to demonstrate a reduction in risk for coronary heart disease (CHD).

7 Compared with cohabiting fathers, mothers had a greater reduction in risk for drug abuse during pregnancy (odds ratio

8 group as the reference, there was a graded and progressive reduction in risk for HF as fitness level was higher.

9 identify high-risk patients with T2DM who have the greatest reduction in risk for HHF with a sodium-glucose cotransporter

10 There was a major reduction in risk for most OIs with ART use in LMICs, with th

11 A possible reduction in risk for pancreatic cancer among people with dia

12 0.67, 95% confidence interval [CI] of 0.54-0.84) and a 56% reduction in risk for POAG endpoints (relative risk = 0.44, 9

13 ence reflected in narrative notes was associated with a 30% reduction in risk for suicide in models adjusted for coded so

14 2 inhibitors in type 2 diabetes mellitus (T2DM), consistent reductions in risks for secondary kidney disease end points (

15 eft bundle branch block (LBBB) did not derive a significant reduction in risk of a HF event/death in the MADIT-CRT trial

16 A 25% reduction in risk of all-cause mortality was found for milk i

17 a 13% reduction in risk of CVD mortality and 2 found a 19% reduction in risk of chronic heart disease (CHD) incidence.

18 habitual intakes of flavan-3-ols were associated with a 13% reduction in risk of CVD mortality and 2 found a 19% reductio

19 ted analyses, DAA therapy was associated with a significant reduction in risk of death (hazard ratio, 0.54; 95% CI, 0.33-

20 chaemic stroke was associated with a small, non-significant reduction in risk of death at 3 years, but among individuals

21 disease receiving oxaliplatin did not exhibit a significant reduction in risk of death in the first 6 years post treatmen

22 CC treatment, DAA therapy was associated with a significant reduction in risk of death.

23 sleep hygiene improvement, is associated with a significant reduction in risk of delirium.

24 e of anthocyanins and flavanones, was associated with a 14% reduction in risk of ED (RR = 0.86; 95% CI: 0.79, 0.92; P = 0

25 hocyanins, and flavones was significantly associated with a reduction in risk of ED only in men <70 y old and not older m

26 rdioverter-defibrillator, was associated with a significant reduction in risk of first and subsequent HHF (first: hazard

27 ), a transplant in the second eye was associated with a 50% reduction in risk of graft failure within 5 years in the firs

28 Early ART initiation was associated with sustained reduction in risk of HIV transmission at 5.5 years (RR, 0.07

29 th CD4 cell counts greater than 500/mm3 and shows sustained reduction in risk of HIV transmission at longer-term follow-u

30 Some further reduction in risk of ischaemic stroke accrued for aspirin onl

31 that for patients treated with alirocumab there would be a reduction in risk of ischemic stroke without increasing hemor

32 additional 5 weeks of gestation were associated with a 14% reduction in risk of lipid disorders (adjusted hazard ratio [

33 ort study identified the minimum weight loss thresholds for reduction in risk of MACE and all-cause mortality in patients

34 there are weight loss-independent factors contributing to a reduction in risk of MACE and all-cause mortality in the surg

35 2013 federal Physical Activity Guidelines resulted in a 35% reduction in risk of mortality.

36 The reduction in risk of recurrent ischaemic stroke at 14 days wa

37 ements before the 12th week of gestation produced a 41%-45% reduction in risk of SPB.

38 rst HHF, CRT-D therapy was associated with a pronounced 44% reduction in risk of subsequent HHF (hazard ratio, 0.56 [95%

39 We observed a long-term reduction in risk of symptomatic dengue virus disease in vacc

40 Statin use was associated with a significant reduction in risk of the specific endpoint of deep vein throm

41 lowest habitual intakes of monomers were associated with a reduction in risk of type 2 diabetes mellitus (T2DM) (n = 5)

42 attributable to vaccine-serotype pneumococci via the joint reduction in risks of carriage and disease progression.

43 ng the log-linear relationship between LDL-C reductions and reductions in risk of atherosclerotic CVD, even in those at v

44 Relative reductions in risk of cardiovascular death, all-cause mortali

45 od pressure-lowering strategies are associated with greater reductions in risk of major cardiovascular and renal events.

46 Results provide strong evidence of a reduction in risk over the season.

47 risk of ED only in men <70 y old and not older men (11-16% reduction in risk; P-interaction = 0.002, 0.03, and 0.007 for

48 Treatment effect for all-cause endpoints was a 33% reduction in risk (relative risk = 0.67, 95% confidence inter

49 18-0.76, P = 0.0068) and 74% (95% CI: 0.07-0.96, P = 0.040) reduction in risk, respectively.

50 More modest reductions in risk were observed after 12 months.